Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center

2015 ◽  
Vol 36 (1) ◽  
pp. 142-147 ◽  
Author(s):  
Yuan-Hong Jiang ◽  
Hueih-Ling Ong ◽  
Hann-Chorng Kuo
Keyword(s):  
Overactive Bladder ◽  
Adverse Events ◽  
Predictive Factors ◽  
Real Life ◽  
Overactive Bladder Syndrome ◽  
Single Center

Onabotulinumtoxina Intravesical Treatment in Patients Affected by Overactive Bladder Syndrome: Best Practice in Real-Life Management

2015 ◽  
Vol 82 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Antonella Giannantoni ◽  
Silvia Proietti ◽  
Elisabetta Costantini ◽  
Marilena Gubbiotti ◽  
Jacopo Rossi De Vermandois ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Best Practice ◽  
Real Life ◽  
Overactive Bladder Syndrome ◽  
Life Management ◽  
Intravesical Treatment

scholarly journals Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Raúl Vozmediano-Chicharro ◽  
Blanca Madurga ◽  
Pedro Blasco
Keyword(s):  
Overactive Bladder ◽  
Adverse Events ◽  
Application Site ◽  
Overactive Bladder Syndrome ◽  
Good Tolerability ◽  
Subgroup Analyses ◽  
Voiding Diary ◽  
Previously Treated ◽  
Clinical Records

Objectives. Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up. Methods. This was a multicenter, retrospective, single-cohort, observational study. Changes in symptoms were evaluated primarily with a 3-day voiding diary. Results were compared to baseline. Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years. Results. Clinical records of 105 patients were examined; 92.4% were women. At 12 months, 58 patients continued to receive transdermal oxybutynin. Changes in symptoms according to the voiding diary were evaluated in 47 patients. Significant improvements from baseline were observed in urinary frequency (−2.6 voids/24 hours (95% CI: −3.5; −1.8), p<0.001); daily number of urgent episodes (−4.7 episodes/day (95% CI: −6.1; −3.6), p<0.001); and urge incontinence (−1.9 episodes/day (95% CI: −2.9; −1.3), p<0.001). No statistically significant differences were found in subgroup analyses. In total, 38.1% of patients had adverse events, primarily in the application site (27.6%). No severe systemic adverse events occurred. Only 6 patients (5.7%) reported dry mouth. Conclusions. Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.

scholarly journals Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Ranran Zhang ◽  
Shan Qiao ◽  
Xiqin Fang ◽  
Kemo Wang ◽  
Yanting Shi ◽  
...  
Keyword(s):  
Adverse Events ◽  
Clinical Judgment ◽  
Prospective Observational Study ◽  
Real Life ◽  
Retention Rates ◽  
Chinese Patients ◽  
Single Center ◽  
Life Conditions ◽  
Clonic Seizures

Purpose: To evaluate the efficacy and tolerability of adjunctive perampanel (PER) in Chinese patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.Methods: Fifty-six patients aged 14–72 years were recruited consecutively in this single-center prospective observational study. All patients received PER as add-on treatment on the basis of clinical judgment. Seizure frequency, adverse events (AEs), and retention rates were obtained at 3 and 6 months after PER introduction.Results: The overall response rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of seizures at the same points were reached in 8 and 15.8%. The retention rates were 89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall incidence of adverse events was 55.4%. The leading reported AEs were dizziness (39.3%) and somnolence (25%).Conclusions: Our study confirmed the efficacy and tolerability of adjunctive PER in Chinese patients in real-life conditions. Based on our treatment experience, a lower maintenance dose of PER would be needed in Chinese patients.

scholarly journals Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience

2020 ◽  
Vol 9 (1) ◽  
pp. IJH23 ◽  
Author(s):  
Vittorio R Zilioli ◽  
Cristina Muzi ◽  
Periana Minga ◽  
Paolo Codega ◽  
Lara Crucitti ◽  
...  
Keyword(s):  
Adverse Events ◽  
Hodgkin’S Lymphoma ◽  
Life Experience ◽  
Real Life ◽  
Nausea And Vomiting ◽  
Hodgkin's Lymphoma ◽  
Single Center ◽  
Noncomparative Study ◽  
Safety And Efficacy ◽  
Chemotherapy Agents

We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin’s lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug–drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.

scholarly journals NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5374-5374
Author(s):  
Vittorio Ruggero Zilioli ◽  
Periana Minga ◽  
Lara Crucitti ◽  
Erika Meli ◽  
Monica Luigia Torretta ◽  
...  
Keyword(s):  
Adverse Events ◽  
Receptor Antagonist ◽  
Primary Endpoint ◽  
Life Experience ◽  
Real Life ◽  
Secondary Endpoint ◽  
Single Center ◽  
First Line ◽  
Before And After ◽  
Chemotherapeutic Treatment

Abstract BACKGROUND In the setting of cHL, ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) is the most widely used first line chemotherapeutic treatment and it is well known that this regimen is associated with a high emetic risk (HEC). Palonosetron (PALO) currently represents one of the most effective and implemented drug for CINV prevention, but after many ABVD cycles patients (pts) frequently need to add other antiemetic drugs to obtain a good control of their symptoms. Netupitant (NETU) is the NK1-RA (neurokinin receptor antagonist) component of NEPA, the first antiemetic drug available as oral fixed combination: NETU (300mg) + PALO (0.5mg). Both ABVD drugs and NETU are metabolized by cytochrome P-450 isoform 3A4 (CYP3A4), but respect to other NK1-receptor antagonist available, NETU has demonstrated to have no clinical relevant interaction with chemotherapy drugs like etoposide, cyclophosphamide and docetaxel. However, no data are currently available about the safety profile of NETU in the setting of ABVD treatment; for that reason we started the use of this drug as salvage therapy after PALO failure. METHODS We retrospectively analyzed the cHL pts treated with ABVD at our Center from September 2016 to January 2018. We used PALO + dexamethasone as first-line anti-CINV prophylaxis, while NEPA was introduced as salvage drug for those pts with inadequately controlled CINV. We collected data regarding demographics; diagnosis; planned chemotherapeutic treatment; performed chemotherapeutic treatment; acute, delayed and anticipatory CINV (before and after NEPA); laboratory findings including transaminases, creatinine and electrolytes (before and after NEPA); adverse reactions (before and after NEPA). The primary endpoint of the study was safety of NEPA in ABVD treated pts, while CINV control (no nausea or vomiting) was the secondary endpoint. NEPA-related safety data have been compared to the same data collected at the moment of the last previous PALO-containing regimen. RESULTS Among the 32 pts treated with ABVD during the study period, 13 (41%) received NEPA. Three pts were males and 10 females, and median age was 33 years (range 18-61). According to disease characteristics at diagnosis the planned ABVD administrations were 12 (6 cycles) in 9 pts, 8 (4 cycles) in 3 pts and 4 (2 cycles) in 1 pt. Nine pts completed the planned chemotherapy, 1 pt skipped the last cycle for personal decision, 3 pts are ongoing treatment at the time of analysis. Reasons for shift to NEPA are as follows: acute (grade 2) CINV alone in 3/13 pts; late (grade 2) CINV alone in 3/13 pts; combined acute (4 grade 2, 1 grade 1) and late (4 grade 2, 1 grade 1) CINV in 5/13 pts; combined anticipatory (grade 1), acute (grade 1) and late (grade 2) CINV in 2/13 pts. NEPA was started after a median of 4 ABVD administrations (range 1-10). Globally 53 NEPA administrations were delivered during subsequent cycles (median number of 3 NEPA administrations for each pt, range 1-11). With regard to the primary endpoint, the observed adverse events are listed in Table 1. With regard to the secondary endpoint, anticipatory, acute and delayed CINV were detected in 15%, 77%, 77%, of PALO pts and 15%, 46% and 15% of NEPA pts, respectively (see Table 2) CONCLUSION In our experience NETU did not show drug-drug interaction with ABVD chemotherapy agents, and NEPA administration was globally well tolerated with mild and transient adverse events. Furthermore, in cHL ABVD treated pts who experienced nausea and/or vomiting after failure of PALO + dexamethasone antiemetic prophylaxis, NEPA has demonstrated to be effective in CINV control. In 4 out of 13 cases, after an initial improvement in CINV control, pts subsequently required to shift to anti-CINV third line treatments. On the other hand, the 9 pts who continued on NEPA administration could experience an optimal CINV control immediately after the first administration. At our knowledge no data have been published regarding NEPA toxicities in the ABVD setting. Our safety and efficacy data come from a real life experience of consecutive pts treated homogeneously at a single center and would suggest the use of NEPA as primary anti-CINV prophylaxis in previously untreated cHL pts. Disclosures Rusconi: Celgene: Research Funding.

scholarly journals Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome

2021 ◽  
Vol 13 ◽  
pp. 175628722110414
Author(s):  
Manon te Dorsthorst ◽  
Michael van Balken ◽  
Dick Janssen ◽  
John Heesakkers ◽  
Frank Martens
Keyword(s):  
Overactive Bladder ◽  
Nerve Stimulation ◽  
Tibial Nerve ◽  
Real Life ◽  
Treatment Modalities ◽  
Overactive Bladder Syndrome ◽  
Tibial Nerve Stimulation ◽  
Significant Difference ◽  
Metabolic Conditions

Introduction and objectives: Overactive bladder syndrome (OAB) is defined as urinary urgency, with or without urgent urinary incontinence; it is often associated with urinary frequency and nocturia, in the absence of any pathological or metabolic conditions that may cause or mimic OAB. The aim of this study was to evaluate the long-term real-life adherence of transcutaneous tibial nerve stimulation (TTNS) in the treatment of OAB, patient satisfaction of the treatment, and reasons for quitting therapy. Materials and methods: In this single center study, all patients who had a positive effect on percutaneous tibial nerve stimulation (PTNS) and continued to receive home-based treatment with TTNS since 2012 were included for analysis. Patients were retrospectively asked to fill out a questionnaire regarding satisfaction, reasons for quitting, and additional or next line of therapy. Results: We included 42 patients for this study, 81% of these patients were female ( n = 34). The median age was 67 years (range 36–86). Most of the patients (64%, n = 27) were diagnosed with OAB wet. The median TTNS treatment persistence was 16 months (range 1–112 months). Reasons and percentages for stopping therapy were: 55% stopped treatment due to loss of effect, and 24% stopped because of preferring other type of neuromodulation. The mean satisfaction score (scale 1–10) in patients who continued TTNS was 6.2 ( n = 9, SD 1.30) versus 5.4 ( n = 29, SD 2.24) for patients who quit therapy. We did not find a statistically significant difference between the two groups ( p = 0.174). Conclusion: TTNS, although effective in the short-term, is not effective in the long-term. In combination with a low satisfaction rate among patients, there is a need for improvement in terms of OAB treatment modalities.

scholarly journals Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: Results of a real-life clinical study

2013 ◽  
Vol 21 (4) ◽  
pp. 389-394 ◽  
Author(s):  
Hironobu Akino ◽  
Mikio Namiki ◽  
Koji Suzuki ◽  
Hideki Fuse ◽  
Yasuhide Kitagawa ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Clinical Study ◽  
Overactive Bladder ◽  
Real Life ◽  
Overactive Bladder Syndrome ◽  
Factors Influencing
Sign in / Sign up

Export Citation Format

Share Document